0001481504false--06-30FY20220.0000150000000003582027702928159600.0000110000000035000007811327932790.000011000000001000000100000010000001000000437501061760541730701760549116104250000001413959P6YP2Y88483332500001562250.0250.0620302475002500001000000025000250003000005000050000300000025005000000250005000000500000050000002225000P3Y535P2Y4000005000000P5Y4800025000000014815042021-10-012021-12-310001481504us-gaap:SeriesAPreferredStockMember2022-02-280001481504us-gaap:SeriesAPreferredStockMember2022-02-012022-02-280001481504us-gaap:ConvertibleNotesPayableMember2022-02-012022-02-280001481504xeri:AmericanAviationTechnologiesLLCMember2021-05-120001481504xeri:SeriesAPreferredSharesMember2021-09-300001481504xeri:SeriesAPreferredSharesMember2021-10-012021-12-310001481504xeri:SeriesAPreferredSharesMember2020-07-012020-09-300001481504xeri:AmericanAviationTechnologiesLLCMember2021-03-310001481504xeri:SeriesAPreferredSharesMember2021-02-150001481504xeri:CommonStockToBeIssued1Memberxeri:TancheOneMember2021-09-300001481504xeri:TrancheTwoMember2021-09-300001481504xeri:TrancheOneMember2021-12-310001481504xeri:TrancheOneMember2021-09-300001481504xeri:SubscriptionAgreementMember2020-07-012020-09-300001481504xeri:WarrantsMembersrt:MaximumMember2021-07-012021-12-310001481504xeri:CommonStockToBeIssued1Memberxeri:SubscriptionAgreementMember2020-07-012020-09-300001481504xeri:CommonStockToBeIssued1Memberxeri:TancheOneMember2020-07-012020-09-300001481504xeri:TrancheTwoMember2021-07-012021-12-310001481504xeri:TrancheTwoMember2021-10-012021-12-310001481504xeri:TrancheOneMember2021-10-012021-12-310001481504xeri:TrancheOneMember2020-07-012020-09-300001481504xeri:SubscriptionAgreementMember2021-07-012021-12-310001481504xeri:WarrantsMembersrt:MinimumMember2021-07-012021-12-310001481504xeri:AdvisoryBoardMembersMember2020-07-012020-09-300001481504xeri:AdvisoryBoardMembersMember2021-07-012021-12-310001481504xeri:CommonStockToBeIssued1Member2020-07-012020-09-300001481504us-gaap:StockOptionMember2021-12-310001481504srt:MaximumMemberus-gaap:StockOptionMember2021-07-012021-12-310001481504srt:MaximumMemberus-gaap:StockOptionMember2021-12-310001481504srt:MinimumMemberus-gaap:StockOptionMember2021-07-012021-12-310001481504srt:MinimumMemberus-gaap:StockOptionMember2021-12-310001481504xeri:FinancialAdvisoryAgreementsOneMember2021-08-012021-08-190001481504xeri:FinancialAdvisoryAgreementsOneMember2021-07-012021-12-310001481504xeri:FinancialAdvisoryAgreementsMember2021-08-112021-11-100001481504xeri:FinancialAdvisoryAgreementsMember2021-07-012021-12-310001481504xeri:AdvisoryBoardMember2021-01-012021-01-180001481504xeri:AdvisoryBoardMember2021-01-012021-01-220001481504xeri:AdvisoryBoardMember2021-02-202021-03-070001481504xeri:AdvisoryBoardMember2020-10-012020-10-270001481504xeri:AdvisoryBoardMember2021-06-202021-07-060001481504xeri:AdvisoryBoardMember2021-08-012021-08-190001481504xeri:AdvisoryBoardMember2021-07-202021-08-090001481504xeri:AdvisoryBoardMember2021-07-012021-07-2800014815042020-07-012020-09-300001481504xeri:JulyOneTwoZeroTwoZeroMemberxeri:AdvisoryBoardMember2020-10-012020-10-270001481504xeri:JulyOneTwoZeroTwoZeroMemberxeri:AdvisoryBoardMember2021-01-012021-01-180001481504xeri:JulyOneTwoZeroTwoZeroMemberxeri:AdvisoryBoardMember2021-01-012021-01-220001481504xeri:JulyOneTwoZeroTwoZeroMemberxeri:AdvisoryBoardMember2020-07-012020-09-300001481504xeri:JulyOneTwoZeroTwoZeroMemberxeri:AdvisoryBoardMember2021-07-012021-12-310001481504xeri:KeystoneBusinessDevelopmentPartnersMember2021-06-300001481504xeri:KeystoneBusinessDevelopmentPartnersMember2019-07-012020-06-300001481504xeri:KeystoneBusinessDevelopmentPartnersMember2020-08-250001481504xeri:KeystoneBusinessDevelopmentPartnersMember2020-11-250001481504xeri:KeystoneBusinessDevelopmentPartnersMember2020-08-012020-08-250001481504xeri:KeystoneBusinessDevelopmentPartnersMember2020-10-012020-12-310001481504xeri:KeystoneBusinessDevelopmentPartnersMember2021-10-012021-12-310001481504xeri:AmpWebServicesMember2020-10-012020-12-310001481504xeri:AmpWebServicesMember2021-10-012021-12-310001481504xeri:EdwardDeFeudisADirectorOfTheCompanyMember2020-10-012020-12-310001481504xeri:EdwardDeFeudisADirectorOfTheCompanyMember2021-10-012021-12-310001481504xeri:AncientInvestmentsLlcMember2020-10-012020-12-310001481504xeri:AncientInvestmentsLlcMember2021-10-012021-12-310001481504xeri:WarrantsMember2021-06-300001481504xeri:FebruaryTwoThousandTwentyTwoMemberxeri:BetweenMarchTwentySevenTwoThousandTwentyAndNovemberTenTwoThousandTwentyMember2021-07-012021-12-3100014815042019-07-012020-03-310001481504xeri:WarrantsMember2021-07-012021-12-310001481504xeri:WarrantsMember2021-12-310001481504xeri:SeptemberTwentySevenTwoThousandTwentyOneMember2021-12-310001481504xeri:SeptemberTwentySevenTwoThousandTwentyOneMember2021-07-012021-12-310001481504xeri:ConvertibleNotesPayableRelatedPartyMemberxeri:AugustTenTwoThousnadTwentyAndJanuaryOneNineTwoThousandTwentyOneMemberxeri:ConversionPriceOneMember2021-12-310001481504xeri:FebruaryTwoThousandTwentyTwoMember2021-08-090001481504xeri:FebruaryTwoThousandTwentyTwoMember2020-07-012020-12-310001481504xeri:FebruaryTwoThousandTwentyTwoMember2021-07-012021-12-310001481504xeri:FebruaryTwoThousandTwentyTwoMember2021-12-310001481504xeri:ConvertibleNotesPayableRelatedPartyMemberxeri:AugustTenTwoThousnadTwentyAndJanuaryOneNineTwoThousandTwentyOneMemberxeri:ConversionPriceThreeMember2021-12-310001481504xeri:ConvertibleNotesPayableRelatedPartyMemberxeri:AugustTenTwoThousnadTwentyAndJanuaryOneNineTwoThousandTwentyOneMember2020-07-012021-03-310001481504xeri:ConvertibleNotesPayableRelatedPartyMemberxeri:AugustTenTwoThousnadTwentyAndJanuaryOneNineTwoThousandTwentyOneMember2021-12-310001481504xeri:FebruaryTwoThousandTwentyTwoMemberxeri:BetweenSeptemberTwentySevenTwentyNineteenAndJulyTwentyTwoThousandTwentyMember2021-07-012021-12-310001481504xeri:FebruaryTwoThousandTwentyTwoMemberxeri:BetweenSeptemberTwentySevenTwentyNineteenAndJulyTwentyTwoThousandTwentyMember2021-12-310001481504xeri:FebruaryTwoThousandTwentyTwoMemberxeri:BetweenSeptemberTwentySevenTwentyNineteenAndJulyTwentyTwoThousandTwentyMember2020-07-012021-03-310001481504xeri:BetweenMarchTwentySevenTwoThousandTwentyAndJulyElevenTwoThousandTwentyOneMember2021-07-012021-12-310001481504xeri:ConvertibleNotesPayablesFourMember2021-06-300001481504xeri:ConvertibleNotesPayablesFourMember2021-12-310001481504xeri:ConvertibleNotesPayablesThreeMember2021-06-300001481504xeri:ConvertibleNotesPayablesThreeMember2021-12-310001481504xeri:ConvertibleNotesPayablesTwoMember2021-06-300001481504xeri:ConvertibleNotesPayablesTwoMember2021-12-310001481504xeri:ConvertibleNotesPayablesOneMember2021-06-300001481504xeri:ConvertibleNotesPayablesOneMember2021-12-310001481504xeri:ConvertibleNotesPayablesFiveMember2021-06-300001481504xeri:ConvertibleNotesPayablesFiveMember2021-12-310001481504xeri:LeaseAgreementMember2021-07-012021-12-310001481504xeri:NovemberOneTwoThousandTwentyOneToOctoberOneTwoThousandTwentyTwoOneMember2021-07-012021-12-310001481504xeri:NovemberOneTwoThousandTwentyOneToOctoberOneTwoThousandTwentyTwoMember2021-07-012021-12-310001481504xeri:NovemberOneTwoThousandTwentyFourToOctoberOneTwoThousandTwentyFiveMember2021-07-012021-12-310001481504xeri:NovemberOneTwoThousandTwentyThreeToOctoberOneTwoThousandTwentyFourMember2021-07-012021-12-310001481504xeri:NovemberOneTwoThousandTwentyToOctoberOneTwoThousandTwentyOneMember2021-07-012021-12-310001481504xeri:FebruaryOneTwoThousandTwentyToOctoberOneTwoThousandTwentyMember2021-07-012021-12-310001481504xeri:JointVentureMember2021-07-012021-12-310001481504xeri:ShareExchangeAgreementMember2019-09-3000014815042020-12-3100014815042020-06-300001481504us-gaap:NoncontrollingInterestMember2021-12-310001481504us-gaap:RetainedEarningsMember2021-12-310001481504us-gaap:TreasuryStockMember2021-12-310001481504us-gaap:AdditionalPaidInCapitalMember2021-12-310001481504us-gaap:CommonStockMember2021-12-310001481504xeri:SeriesBPreferredStockShareMember2021-12-310001481504xeri:SeriesAPreferredStockSharesMember2021-12-310001481504us-gaap:NoncontrollingInterestMember2021-10-012021-12-310001481504us-gaap:RetainedEarningsMember2021-10-012021-12-310001481504us-gaap:TreasuryStockMember2021-10-012021-12-310001481504us-gaap:AdditionalPaidInCapitalMember2021-10-012021-12-310001481504us-gaap:CommonStockMember2021-10-012021-12-310001481504xeri:SeriesBPreferredStockShareMember2021-10-012021-12-310001481504xeri:SeriesAPreferredStockSharesMember2021-10-012021-12-3100014815042021-09-300001481504us-gaap:NoncontrollingInterestMember2021-09-300001481504us-gaap:RetainedEarningsMember2021-09-300001481504us-gaap:TreasuryStockMember2021-09-300001481504us-gaap:AdditionalPaidInCapitalMember2021-09-300001481504us-gaap:CommonStockMember2021-09-300001481504xeri:SeriesBPreferredStockShareMember2021-09-300001481504xeri:SeriesAPreferredStockSharesMember2021-09-3000014815042021-07-012021-09-300001481504us-gaap:NoncontrollingInterestMember2021-07-012021-09-300001481504us-gaap:RetainedEarningsMember2021-07-012021-09-300001481504us-gaap:TreasuryStockMember2021-07-012021-09-300001481504us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001481504us-gaap:CommonStockMember2021-07-012021-09-300001481504xeri:SeriesBPreferredStockShareMember2021-07-012021-09-300001481504xeri:SeriesAPreferredStockSharesMember2021-07-012021-09-300001481504us-gaap:NoncontrollingInterestMember2021-06-300001481504us-gaap:RetainedEarningsMember2021-06-300001481504us-gaap:TreasuryStockMember2021-06-300001481504us-gaap:AdditionalPaidInCapitalMember2021-06-300001481504us-gaap:CommonStockMember2021-06-300001481504xeri:SeriesBPreferredStockShareMember2021-06-300001481504xeri:SeriesAPreferredStockSharesMember2021-06-3000014815042020-07-012020-12-3100014815042021-07-012021-12-3100014815042020-10-012020-12-310001481504xeri:SeriesBPreferredSharesMember2021-06-300001481504xeri:SeriesBPreferredSharesMember2021-12-310001481504xeri:SeriesAPreferredSharesMember2021-06-300001481504xeri:SeriesAPreferredSharesMember2021-12-3100014815042021-06-3000014815042021-12-3100014815042022-02-12iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
☒
|
Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
|
For the quarterly period ended December 31, 2021
☐
|
Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
|
For the transition period from __________ to __________.
Commission File Number: 000-54277
XERIANT,
INC.
|
(Exact name of registrant as specified in its charter).
|
Nevada
|
|
27-1519178
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
Innovation Centre #13998 FAU Boulevard,
Suite 309
Boca Raton, Florida
|
|
33431
|
(Address of principal executive offices)
|
|
(Zip code)
|
Registrant’s telephone number, including area code:
(561)
491-9595
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading symbol
|
|
Name of exchange
on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports) and (2) has been subject to such filing requirements
for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the
registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, a
smaller reporting company, and an “emerging growth company” in Rule
12b-2 of the Exchange Act.
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
Non-accelerated Filer
|
☐
|
Smaller reporting company
|
☒
|
Emerging growth company
|
☐
|
|
|
If
an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition 13(a) of
the Securities Act. ☐
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Indicate the number of shares outstanding of each of the issuer’s
classes of common stock, as of the latest practicable date. As of
February 12, 2022, the Registrant had outstanding 364,278,386
shares of common stock.
XERIANT, INC.
FORM 10-Q
TABLE OF CONTENTS
SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS
This document contains certain statements of a forward-looking
nature. Such forward-looking statements, including but not limited
to statements regarding projected growth, trends and strategies,
future operating and financial results, financial expectations and
current business indicators are based upon current information and
expectations and are subject to change based on factors beyond the
control of the Company. Forward-looking statements typically are
identified by the use of terms such as “look,” “may,” “should,”
“might,” “believe,” “plan,” “expect,” “anticipate,” “estimate” and
similar words, although some forward-looking statements are
expressed differently. The accuracy of such statements may be
impacted by a number of risks and uncertainties that could cause
actual results to differ materially from those projected or
anticipated, including but not limited to those set forth herein
and in our Annual Report on Form 10-K.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Except as required by the federal securities laws, we undertake no
obligation to update forward-looking information. Nonetheless, the
Company reserves the right to make such updates from time to time
by press release, periodic report or other method of public
disclosure without the need for specific reference to this Report.
No such update shall be deemed to indicate that other statements
not addressed by such update remain correct or create an obligation
to provide any other updates.
PART I – FINANCIAL
INFORMATION
Item 1. Financial
statements
XERIANT, INC.
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021
(UNAUDITED)
INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
XERIANT, INC. AND SUBSIDIARY
|
CONDENSED CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
As of
December 31, 2021
|
|
|
As of
June 30, 2021
|
|
Assets
|
|
(Unaudited)
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
Cash
|
$ |
2,110,549 |
|
|
$ |
962,540 |
|
Deposits
|
|
|
12,546 |
|
|
|
12,546 |
|
Prepaids
|
|
|
2,823 |
|
|
|
1,234 |
|
Total current assets
|
|
|
2,125,918 |
|
|
|
976,320 |
|
Property & equipment, net
|
|
|
4,907 |
|
|
|
|
|
Operating lease right-of-use asset
|
|
|
149,310 |
|
|
|
169,209 |
|
Total assets
|
|
$ |
2,280,135 |
|
|
$ |
1,145,529 |
|
|
|
|
|
|
|
|
|
|
Liabilities & stockholders’ deficit
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
$ |
23,744 |
|
|
$ |
73,224 |
|
Accrued liabilities, related party
|
|
|
30,000 |
|
|
|
25,000 |
|
Convertible notes payable, net of discount
|
|
|
721,055 |
|
|
|
158,196 |
|
Lease liability, current
|
|
|
45,720 |
|
|
|
42,643 |
|
Total current liabilities
|
|
|
820,519 |
|
|
|
299,063 |
|
|
|
|
|
|
|
|
|
|
Lease liability, long-term
|
|
|
117,585 |
|
|
|
141,160 |
|
Total liabilities
|
|
|
938,104 |
|
|
|
440,223 |
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Note 8)
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ deficit
|
|
|
|
|
|
|
|
|
Series A Preferred stock, $0.00001 par value; 100,000,000
authorized; 3,500,000 designated; 781,132 and 793,279 shares issued
and outstanding at December 31, 2021 and June 30, 2021,
respectively
|
|
|
8 |
|
|
|
8 |
|
Series B Preferred stock, $0.00001 par value; 100,000,000
authorized; 1,000,000 designated; 1,000,000 shares issued and
outstanding at December 31, 2021 and June 30, 2021,
respectively
|
|
|
10 |
|
|
|
10 |
|
Common stock, $0.00001 par value; 5,000,000,000 shares authorized;
358,202,770 and 292,815,960 shares issued and outstanding at
December 31, 2021 and June 30, 2021, respectively
|
|
|
3,577 |
|
|
|
2,925 |
|
Common stock to be issued
|
|
|
347,900 |
|
|
|
51,090 |
|
Additional paid in capital
|
|
|
14,451,855 |
|
|
|
4,138,194 |
|
Accumulated deficit
|
|
|
(10,029,764 |
) |
|
|
(3,270,235 |
) |
Total Xeriant stockholder’s deficit
|
|
|
4,773,586 |
|
|
|
921,992 |
|
Non-controlling interest
|
|
|
(3,431,555 |
) |
|
|
(216,686 |
) |
Total stockholders’ deficit
|
|
|
1,342,031 |
|
|
|
705,306 |
|
Total liabilities and stockholders’ deficit
|
|
$ |
2,280,135 |
|
|
$ |
1,145,529 |
|
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
XERIANT, INC. AND SUBSIDIARY
|
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS
|
(UNAUDITED)
|
|
|
|
For the three months ended
|
|
|
For the three months ended
|
|
|
For the six
months ended
|
|
|
|
December 31,
2021
|
|
|
December 31,
2020
|
|
|
December 31,
2021
|
|
|
December 31,
2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing expense
|
|
$ |
46,623 |
|
|
$ |
1,027,109 |
|
|
$ |
645,218 |
|
|
$ |
1,027,109 |
|
General and administrative expenses
|
|
|
1,120,250 |
|
|
|
37,469 |
|
|
|
2,321,252 |
|
|
|
73,439 |
|
Professional fees
|
|
|
102,484 |
|
|
|
14,637 |
|
|
|
132,025 |
|
|
|
35,237 |
|
Related party consulting fees
|
|
|
130,925 |
|
|
|
41,500 |
|
|
|
213,425 |
|
|
|
78,000 |
|
Research and development expense
|
|
|
2,859,644 |
|
|
|
0 |
|
|
|
5,200,219 |
|
|
|
0 |
|
Total operating expenses
|
|
|
4,259,926 |
|
|
|
1,120,715 |
|
|
|
8,512,139 |
|
|
|
1,213,785 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(4,259,926 |
) |
|
|
(1,120,715 |
) |
|
|
(8,512,139 |
) |
|
|
(1,213,785 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of debt discount
|
|
|
(1,264,931 |
) |
|
|
(66,449 |
) |
|
|
(1,413,959 |
) |
|
|
(112,410 |
) |
Amortization of debt discount, related party
|
|
|
(0) |
|
|
|
(3,044 |
) |
|
|
(0) |
|
|
|
(5,000 |
) |
Financing fees
|
|
|
0 |
|
|
|
|
|
|
|
(43,750 |
) |
|
|
0 |
|
Interest expense
|
|
|
(1,625 |
) |
|
|
(1,139 |
) |
|
|
(4,014 |
) |
|
|
(2,196 |
) |
Interest expense, related party
|
|
|
0 |
|
|
|
(46 |
) |
|
|
0 |
|
|
|
(76 |
) |
Gain on forgiveness of accounts payable
|
|
|
0 |
|
|
|
(1,956 |
) |
|
|
0 |
|
|
|
0 |
|
Loss on settlement of debt
|
|
|
(4 |
) |
|
|
0 |
|
|
|
(536 |
) |
|
|
(186,954 |
) |
Total other (expense)
|
|
|
(1,266,560 |
) |
|
|
(72,634 |
) |
|
|
(1,462,259 |
) |
|
|
(306,636 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-controlling interest
|
|
|
(2,037,053 |
) |
|
|
|
|
|
|
(3,214,869 |
) |
|
|
0 |
|
Common stockholders
|
|
|
(3,489,430 |
) |
|
|
|
|
|
|
(6,759,529 |
) |
|
|
0 |
|
Net loss
|
|
$ |
(5,526,486 |
) |
|
$ |
(1,193,349 |
) |
|
$ |
(9,974,398 |
) |
|
$ |
(1,520,421 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share - basic and diluted
|
|
$ |
(0.02 |
) |
|
$ |
(0.01 |
) |
|
$ |
(0.03 |
) |
|
$ |
(0.01 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares outstanding - basic and
diluted
|
|
|
352,796,331 |
|
|
|
234,451,953 |
|
|
|
328,392,903 |
|
|
|
176,685,459 |
|
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
XERIANT, INC. AND
SUBSIDIARY
|
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN
STOCKHOLDERS’ DEFICIT
|
'FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31,
2021
(UNAUDITED)
|
|
|
Series A Preferred Stock
|
|
|
Series B
Preferred Stock
|
|
|
Common stock
|
|
|
Additional
Paid in
|
|
|
Stock
|
|
|
Accumulated
|
|
|
Non-Controlling
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
|
|
|
Deficit
|
|
|
Interest
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance June 30, 2021
|
|
|
788,270 |
|
|
|
8 |
|
|
|
1,000,000 |
|
|
|
10 |
|
|
|
292,815,960 |
|
|
|
2,925 |
|
|
$
|
4,138,194 |
|
|
$
|
51,090 |
|
|
$
|
(3,270,235 |
) |
|
$
|
(216,686 |
) |
|
$
|
705,306 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock committed in prior period
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
400,000 |
|
|
|
4 |
|
|
|
47,996 |
|
|
|
(48,000 |
) |
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sale of common stock
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
7,500,000 |
|
|
|
75 |
|
|
|
499,925 |
|
|
|
1,168,500 |
|
|
|
0 |
|
|
|
0 |
|
|
|
1,668,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued as equity kicker
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
250,000 |
|
|
|
3 |
|
|
|
43,750 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
43,753 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise of warrants
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
4,185,000 |
|
|
|
41 |
|
|
|
125,509 |
|
|
|
3,000 |
|
|
|
0 |
|
|
|
0 |
|
|
|
128,550 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of Series A Preferred to Common Stock
|
|
|
(4,000 |
) |
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
4,000,000 |
|
|
|
40 |
|
|
|
(40 |
) |
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of convertible notes and accrued interest
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
10,598,544 |
|
|
|
106 |
|
|
|
176,054 |
|
|
|
(3,090 |
) |
|
|
0 |
|
|
|
0 |
|
|
|
173,070 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock issued for services
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
2,825,000 |
|
|
|
27 |
|
|
|
449,173 |
|
|
|
91,900 |
|
|
|
0 |
|
|
|
0 |
|
|
|
541,100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock option compensation
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
1,060,324 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
1,060,324 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of beneficial conversion feature associated with
convertible debt
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
250,000 |
|
|
|
0 |
|
|
|
0 |
|
|
0
|
|
|
|
250,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
(3,270,099 |
) |
|
|
(1,177,816 |
) |
|
|
(4,447,915 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance September 30, 2021
|
|
|
784,270 |
|
|
$ |
8 |
|
|
|
1,000,000 |
|
|
$ |
10 |
|
|
|
322,574,504 |
|
|
$ |
3,221 |
|
|
$ |
6,790,885 |
|
|
$ |
1,263,400 |
|
|
$ |
(6,540,334 |
) |
|
$ |
(1,394,502 |
) |
|
$ |
122,688 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock committed in prior period
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
23,266,666 |
|
|
|
233 |
|
|
|
1,162,267 |
|
|
|
(1,162,500 |
) |
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sale of common stock
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
8,200,000 |
|
|
|
82 |
|
|
|
409,918 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
410,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise of warrants
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
123,600 |
|
|
|
1 |
|
|
|
2,999 |
|
|
|
(3,000 |
) |
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of Series A Preferred to Common Stock
|
|
|
(3,138 |
) |
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
3,138,000 |
|
|
|
31 |
|
|
|
(31 |
) |
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of convertible notes and accrued interest
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
0 |
|
|
|
250,000 |
|
|
|
0 |
|
|
|
0 |
|
|
|
250,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock issued for services
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
900,000 |
|
|
|
9 |
|
|
|
116,095 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
116,104 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock option compensation
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
827,221 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
827,221 |
|
Fair value of warrants associated with convertible debt
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
2,777,081 |
|
|
|
0 |
|
|
|
0 |
|
|
0
|
|
|
|
2,777,081 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of beneficial conversion feature associated with
convertible debt
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
2,365,419 |
|
|
|
0 |
|
|
|
0 |
|
|
0
|
|
|
|
2,365,419 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
- |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
(3,489,430 |
) |
|
|
(2,037,053 |
) |
|
|
(5,526,483 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance December 31, 2021
|
|
|
781,132 |
|
|
$ |
8 |
|
|
|
1,000,000 |
|
|
$ |
10 |
|
|
|
358,202,770 |
|
|
$ |
3,577 |
|
|
$ |
14,451,855 |
|
|
$ |
347,900 |
|
|
$ |
(10,029,764 |
) |
|
$ |
(3,431,555 |
) |
|
$ |
1,342,031 |
|
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
XERIANT, INC. AND SUBSIDIARY
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS
|
(Unaudited)
|
|
|
For the six months ended
|
|
|
|
December 31,
2021
|
|
|
December 31,
2020
|
|
|
|
|
|
|
|
|
Cash Flows from Operating Activities
|
|
|
|
|
|
|
Net Loss
|
|
$ |
(9,974,398 |
) |
|
$ |
(1,520,421 |
) |
Adjustments to reconcile net loss to net cash used by
operating activities:
|
|
|
|
|
|
|
|
|
Depreciation and Amortization
|
|
|
83 |
|
|
|
- |
|
Stock compensation expense
|
|
|
1,887,545 |
|
|
|
1,027,109 |
|
Stock issued for services
|
|
|
657,204 |
|
|
|
- |
|
Financing fees
|
|
|
43,750 |
|
|
|
- |
|
Loss on settlement of debt
|
|
|
0 |
|
|
|
186,954 |
|
Amortization of Debt Discount
|
|
|
1,413,959 |
|
|
|
112,410 |
|
Amortization of Debt Discount, Related Party
|
|
|
0 |
|
|
|
5,000 |
|
Changes in operating assets & liabilities
|
|
|
|
|
|
|
|
|
Operating lease right of use asset
|
|
|
19,899 |
|
|
|
247 |
|
Lease liabilities
|
|
|
(20,498 |
) |
|
|
- |
|
Deposits and prepaids
|
|
|
(1,589 |
) |
|
|
271 |
|
Accounts payable and accrued liabilities
|
|
|
(49,475 |
) |
|
|
25,873 |
|
Accrued liability, related party
|
|
|
5,000 |
|
|
|
- |
|
Accrued expenses
|
|
|
5,520 |
|
|
|
- |
|
Net cash used by operating activities
|
|
|
(6,013,001 |
) |
|
|
(162,557 |
) |
|
|
|
|
|
|
|
|
|
Cash Flows from Investing Activities
|
|
|
|
|
|
|
|
|
Purchase of property and equipment
|
|
|
(4,990 |
) |
|
|
0 |
|
Net cash used in financing activities
|
|
|
(4,990 |
) |
|
|
0 |
|
|
|
|
|
|
|
|
|
|
Cash Flows from Financing Activities
|
|
|
|
|
|
|
|
|
Sale of common stock
|
|
|
2,078,500 |
|
|
|
51,000 |
|
Cash from exercise of warrants
|
|
|
128,550 |
|
|
|
0 |
|
Proceeds from convertible notes payable
|
|
|
4,958,950 |
|
|
|
92,300 |
|
Net cash provided by financing activities
|
|
|
7,166,000 |
|
|
|
143,300 |
|
|
|
|
|
|
|
|
|
|
Increase in Cash
|
|
|
1,148,009 |
|
|
|
(19,257 |
) |
|
|
|
|
|
|
|
|
|
Cash at beginning of period
|
|
|
962,540 |
|
|
|
38,893 |
|
|
|
|
|
|
|
|
|
|
Cash at end of period
|
|
$ |
2,110,549 |
|
|
$ |
19,636 |
|
|
|
|
|
|
|
|
|
|
Supplemental Cash Flow Information
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$ |
0 |
|
|
$ |
0 |
|
Cash paid for income taxes
|
|
$ |
0 |
|
|
$ |
0 |
|
|
|
|
|
|
|
|
|
|
Non-cash investing and financing activities:
|
|
|
|
|
|
|
|
|
Conversion of convertible notes payable and accrued interest
|
|
$ |
437,246 |
|
|
$ |
129,859 |
|
Warrants issued with convertible notes payable
|
|
$ |
2,777,081 |
|
|
$ |
42,795 |
|
Beneficial conversion feature arising from convertible notes
payable
|
|
$ |
2,615,419 |
|
|
$ |
49,505 |
|
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
XERIANT, INC. AND
SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
NOTE 1 - ORGANIZATION AND NATURE OF BUSINESS
Xeriant, Inc. (“Xeriant” or the “Company”) is an aerospace company
dedicated to the emerging aviation market called Advanced Air
Mobility (AAM), the transition to eco-friendly, on demand flight,
making air transportation more accessible and a greater part of our
daily lives. Xeriant is focused on the acquisition, development,
and proliferation of next generation hybrid-electric and fully
electric aircraft with vertical takeoff and landing (eVTOL)
capabilities, performance enhancing aerospace technologies and
advanced materials, as well as critical support infrastructure.
Xeriant is located at the Research Park at Florida Atlantic
University in Boca Raton, Florida adjacent to the Boca Raton
Airport, and trades on OTC Markets under the stock symbol, XERI.
The Company was incorporated in Nevada on December 18, 2009.
On April 16, 2019, the Company and the members of American Aviation
Technologies, LLC (“AAT”) entered into a Share Exchange Agreement
(“Agreement”). The Agreement, which became effective on September
30, 2019, was pursuant to which the Company acquired 100% of the
issued and outstanding membership units in exchange for the
issuance of shares of the Company’s Series A Preferred Stock
constituting 86.39% of the total voting power of the Company’s
capital stock to be outstanding upon closing, after giving effect
to the consummation of concurrent debt settlement and other capital
stock issuances but before the issuance of shares of capital stock
for investor relations purposes. As a result of the Exchange
Agreement, AAT became a wholly owned subsidiary of the Company.
On
June 22, 2020, the name of the Company was changed to Xeriant, Inc.
in the State of Nevada and subsequently approved by FINRA effective
July 30, 2020 for the name and symbol change (XERI).
On
May 27, 2021, the Company entered into a Joint Venture Agreement
with XTI Aircraft Company, to form a new company, called Eco-Aero,
LLC, for purpose of completing the preliminary design of XTI’s
TriFan 600, a 5-passenger plus pilot, hybrid electric, vertical
takeoff and landing (eVTOL) fixed wing aircraft.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES
Basis of
Presentation
The unaudited condensed consolidated financial statements of the
Company and the accompanying notes included in this Quarterly
Report are unaudited. In the opinion of management, all adjustments
necessary for a fair presentation of the unaudited consolidated
condensed financial statements have been included. Such adjustments
are of a normal, recurring nature. The unaudited condensed
consolidated financial statements, and the accompanying notes, are
prepared in accordance with generally accepted accounting
principles in the United States (“GAAP”). Results for the interim
periods presented are not necessarily indicative of the results
that might be expected for the entire fiscal year. These financial
statements should be read in conjunction with the company’s latest
annual financial statements.
Principles of
Consolidation
The condensed consolidated unaudited financial statements include
the accounts of Xeriant, Inc., American Aviation Technologies, LLC,
and Eco-Aero, LLC. All material intercompany accounts, transactions
and profits were eliminated in consolidation. These financial
statements should be read in conjunction with the company’s latest
annual financial statements.
Use of Estimates
The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and
expenses during the reporting period. The most significant
assumptions and estimates relate to the valuation of beneficial
conversion features and warrants associated with convertible debt.
Actual results could differ from these estimates.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(CONTINUED)
Fair Value Measurements and
Fair Value of Financial Instruments
The Company adopted ASC Topic 820, Fair Value Measurements. ASC
Topic 820 clarifies the definition of fair value, prescribes
methods for measuring fair value, and establishes a fair value
hierarchy to classify the inputs used in measuring fair value as
follows:
Level 1: Inputs are unadjusted quoted prices in active markets for
identical assets or liabilities available at the measurement
date.
Level 2: Inputs are unadjusted quoted prices for similar assets and
liabilities in active markets, quoted prices for identical or
similar assets and liabilities in markets that are not active,
inputs other than quoted prices that are observable, and inputs
derived from or corroborated by observable market data.
Level 3: Inputs are unobservable inputs which reflect the reporting
entity’s own assumptions on what assumptions the market
participants would use in pricing the asset or liability based on
the best available information.
The estimated fair value of certain financial instruments,
including all current liabilities are carried at historical cost
basis, which approximates their fair values because of the
short-term nature of these instruments.
Deferred Taxes
The Company follows Accounting Standards Codification subtopic
740-10, Income Taxes (“ASC 740-10”) for recording the provision for
income taxes. Deferred tax assets and liabilities are computed
based upon the difference between the financial statement and
income tax basis of assets and liabilities using the enacted
marginal tax rate applicable when the related asset or liability is
expected to be realized or settled. Deferred income tax expenses or
benefits are based on the changes in the asset or liability during
each period. If available evidence suggests that it is more likely
than not that some portion or all of the deferred tax assets will
not be realized, a valuation allowance is required to reduce the
deferred tax assets to the amount that is more likely than not to
be realized. Future changes in such valuation allowance are
included in the provision for deferred income taxes in the period
of change. Deferred income taxes may arise from temporary
differences resulting from income and expense items reported for
financial accounting and tax purposes in different periods.
Deferred taxes are classified as current or non-current, depending
on the classification of assets and liabilities to which they
relate. Deferred taxes arising from temporary differences that are
not related to an asset or liability are classified as current or
non-current depending on the periods in which the temporary
differences are expected to reverse and are considered immaterial.
As of December 31, 2021 and June 30, 2021 there are no deferred tax
assets.
Cash and Cash
Equivalents
For purposes of the Statements of Cash Flows, the Company considers
highly liquid investments with an original maturity of three months
or less to be cash equivalents. The Company has no cash
equivalents.
Accounts Receivable and
Allowance for Doubtful Accounts
The Company monitors outstanding receivables based on factors
surrounding the credit risk of specific customers, historical
trends, and other information. The allowance for doubtful accounts
is estimated based on an assessment of the Company’s ability to
collect on customer accounts receivable. There is judgment involved
with estimating the allowance for doubtful accounts and if the
financial condition of the Company’s customers were to deteriorate,
resulting in their inability to make the required payments, the
Company may be required to record additional allowances or charges
against revenues. The Company writes-off accounts receivable
against the allowance when it determines a balance is uncollectible
and no longer actively pursues its collection. The allowance for
doubtful accounts is created by forming a credit balance which is
deducted from the total receivables balance in the balance sheet.
As of December 31, 2021 and June 30, 2021 there are no accounts
receivable.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(CONTINUED)
Revenue
Recognition
Revenue includes product sales. The Company recognizes revenue from
product sales in accordance with Topic 606 “Revenue Recognition in
Financial Statements” which considers revenue realized or
realizable and earned when all of the following criteria are
met:
|
(i)
|
persuasive evidence of an arrangement exists,
|
|
(ii)
|
the services have been rendered and all required milestones
achieved,
|
|
(iii)
|
the sales price is fixed or determinable, and
|
|
(iv)
|
Collectability is reasonably assured.
|
For the six months ended December 31, 2021 and 2020, the Company
has no revenue.
Convertible
Debentures
If
the conversion features of conventional convertible debt provide
for a rate of conversion that is below market value at issuance,
this feature is characterized as a beneficial conversion feature
(“BCF”). A BCF is recorded by the Company as a debt discount
pursuant to ASC Topic 470-20 “Debt with Conversion and Other
Options.” In those circumstances, the convertible debt is recorded
net of the discount related to the BCF, and the Company amortizes
the discount to interest expense, over the life of the debt. During
the six months ended December 31, 2021, the Company recorded a BCF
in the amount of $2,365,419.
Fair Value of Financial
Instruments
Accounting Standards Codification subtopic 825-10, Financial
Instruments (“ASC 825-10”) requires disclosure of the fair value of
certain financial instruments. The carrying value of cash, accounts
payable and accrued liabilities as reflected in the balance sheets,
approximate fair value because of the short-term maturity of these
instruments. All other significant financial assets, financial
liabilities and equity instruments of the Company are either
recognized or disclosed in the financial statements together with
other information relevant for making a reasonable assessment of
future cash flows, interest rate risk and credit risk. Where
practicable the fair values of financial assets and financial
liabilities have been determined and disclosed; otherwise only
available information pertinent to fair value has been
disclosed.
The Company follows Accounting Standards Codification subtopic
820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and
Accounting Standards Codification subtopic 825-10, Financial
Instruments (“ASC 825-10”), which permits entities to choose to
measure many financial instruments and certain other items at fair
value.
Research and Development
Expenses
Expenditures for research and development are expensed as incurred.
The Company incurred research and development expenses of
$5,200,219 and $0 for the six months ended December 31, 2021 and
2020, respectively.
Advertising, Marketing and
Public Relations
The Company expenses advertising and marketing costs as they are
incurred. The Company recorded advertising expenses in the amount
of $164,713 and $0 for the six months ended December 31, 2021 and
2020, respectively. These expenses are included within sales in
marketing expenses in the statements of operations.
Offering Costs
Costs incurred in connection with raising capital by the issuance
of common stock are recorded as contra equity and deducted from the
capital raised. There were no offering costs for the six months
ended December 31, 2021 and 2020, respectively.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(CONTINUED)
The Company recognizes the effect of income tax positions only if
those positions are more likely than not of being sustained.
Recognized income tax positions are measured at the largest amount
that is greater than 50% likely of being realized. Changes in
recognition or measurement are reflected in the period in which the
change in judgment occurs. The Company records interest and
penalties related to unrecognized tax benefits as a component of
general and administrative expenses. Our consolidated federal tax
return and any state tax returns are not currently under
examination.
The Company has adopted FASB ASC 740-10, Accounting for Income
Taxes, which requires an asset and liability approach to financial
accounting and reporting for income taxes. Deferred income tax
assets and liabilities are computed annually from differences
between the financial statement and tax basis of assets and
liabilities that will result in taxable or deductible amounts in
the future based on enacted tax laws and rates applicable to the
periods in which the differences are expected to affect taxable
income. Valuation allowances are established when necessary to
reduce deferred tax assets to the amount expected to be
realized.
Recent Accounting
Pronouncements
In
August 2020, the Financial Accounting Standards Board (“FASB”)
issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40)
(“ASU 2020-06”) to simplify accounting for certain financial
instruments. ASU 2020-06 eliminates the current models that require
separation of beneficial conversion and cash conversion features
from convertible instruments and simplifies the derivative scope
exception guidance pertaining to equity classification of contracts
in an entity’s own equity. The new standard also introduces
additional disclosures for convertible debt and freestanding
instruments that are indexed to and settled in an entity’s own
equity. ASU 2020-06 amends the diluted earnings per share guidance,
including the requirement to use the if-converted method for all
convertible instruments. ASU 2020-06 is effective January 1, 2024
and should be applied on a full or modified retrospective basis,
with early adoption permitted beginning on January 1, 2021. The
adoption of ASU 2020-06 is expect to have material impact on the
Company’s financial statements.
The Company has implemented all new accounting pronouncements that
are in effect. These pronouncements did not have any material
impact on the consolidated financial statements unless otherwise
disclosed, and the Company does not believe that there are any
other new accounting pronouncements that have been issued that
might have a material impact on its financial position or results
of operations.
NOTE 3 - JOINT VENTURE
On
May 31, 2021, the Company entered into a Joint Venture Agreement
(the “Agreement”) with XTI Aircraft Company (“XTI”), a Delaware
corporation, to form a new company, called Eco-Aero, LLC (the
“JV”), a Delaware limited liability company, with the purpose of
completing the preliminary design of XTI’s TriFan 600, a
5-passenger plus pilot, hybrid electric, vertical takeoff, and
landing (eVTOL) fixed wing aircraft. Under the Agreement, Xeriant
is contributing capital, technology, and strategic business
relationships, and XTI is contributing intellectual property
licensing rights and know-how. XTI and the Company each own 50
percent of the JV. The JV is managed by a management committee
consisting of five members, three appointed by the Company and two
by XTI. The Agreement was effective on June 4, 2021, with an
initial deposit of $1 million into the JV. Xeriant’s financial
commitment is $10 million, contributed over a period of less than
one year, as required by the aircraft development timeline and
budget.
The Company analyzed the transaction under ASC 810
Consolidation, to determine if the joint venture
classifies as a Variable Interest Entity (“VIE”). The Joint Venture
qualifies as a VIE based on the fact the JV does not have
sufficient equity to operate without financial support from
Xeriant. According to ASC 810-25-38, a reporting entity shall
consolidate a VIE when that reporting entity has a variable
interest (or combination of variable interests) that provides the
reporting entity with a controlling financial interest on the basis
of the provisions in paragraphs 810-10-25-38A through 25-38J. The
reporting entity that consolidates a VIE is called the primary
beneficiary of that VIE. According to the JV operating agreement,
the ownership interests are 50/50. However, the agreement provides
for a Management Committee of five members. Three of the five
members are from Xeriant. Additionally, Xeriant has an obligation
to invest $10,000,000 into the JV. As such, Xeriant has substantial
capital at risk. Based on these two factors, the conclusion is that
Xeriant is the primary beneficiary of the VIE. Accordingly, Xeriant
has consolidated the VIE.
NOTE 4 - CONCENTRATION OF CREDIT RISKS
The Company maintains accounts with financial institutions. All
cash in checking accounts is non-interest bearing and is fully
insured by the Federal Deposit Insurance Corporation (FDIC). At
times, cash balances may exceed the maximum coverage provided by
the FDIC on insured depositor accounts. The Company believes it
mitigates its risk by depositing its cash and cash equivalents with
major financial institutions. On December 31, 2021, the Company had
$1,855,883 in excess of FDIC insurance.
NOTE 5 - OPERATING LEASE RIGHT-OF-USE ASSET AND
OPERATING LEASE LIABILITY
The Company leases 2,911 square feet of office space located in the
Research Park at Florida Atlantic University, Innovation Centre 1,
3998 FAU Boulevard, Suite 309, Boca Raton, Florida. The Company
entered into a lease agreement commencing on November 1, 2019
through January 1, 2025 in which the first three months of rent
were abated. Due to the COVID-19 pandemic, the Company decided to
have all employees work from home and intends to build out the
office space by the end of 2021 to allow employees to work from the
office in 2022 as COVID-19 cases went up significantly in the first
quarter of 2022. The following table illustrates the base rent
amounts over the term of the lease:
|
|
Base
|
|
Rent Periods
|
|
Rent
|
|
February 1, 2020 to October 1, 2020
|
|
$ |
4,367 |
|
November 1, 2020 to October 1, 2021
|
|
$ |
4,498 |
|
November 1, 2021 to October 1, 2022
|
|
$ |
4,633 |
|
November 1, 2021 to October 1, 2022
|
|
$ |
4,771 |
|
November 1, 2023 to October 1, 2024
|
|
$ |
4,915 |
|
November 1, 2024 to January 1, 2025
|
|
$ |
5,063 |
|
Operating lease right-of-use asset and liability are recognized at
the present value of the future lease payments at the lease
commencement date. The interest rate used to determine the present
value is our incremental borrowing rate, estimated to be 10%, as
the interest rate implicit in most of our leases is not readily
determinable. Operating lease expense is recognized on a
straight-line basis over the lease term. Since the common area
maintenance expenses are expenses that do not depend on an index or
rate, they are excluded from the measurement of the lease liability
and recognized in other general and administrative expenses on the
statements of operations. At inception the Company paid prepaid
rent in the amount of $4,659, which was netted against the
operating lease right-of-use asset balance until it was applied in
February 2020.
Right-of-use asset is summarized below:
|
|
December 31,
|
|
|
|
2021
|
|
Office lease
|
|
$ |
220,448 |
|
Less: accumulated amortization
|
|
|
(71,138 |
) |
Right-of-use asset, net
|
|
$ |
149,310 |
|
Operating lease liability is summarized below:
|
|
December 31,
2021
|
|
Office lease
|
|
$ |
163,305 |
|
Less: current portion
|
|
|
(45,720 |
) |
Long term portion
|
|
|
117,585 |
|
Maturity of the lease liability is as follows:
Fiscal year ending June 30, 2022
|
|
$ |
29,607 |
|
Fiscal year ending June 30, 2023
|
|
|
60,392 |
|
Fiscal year ending June 30, 2024
|
|
|
62,201 |
|
Fiscal year ending June 30, 2025
|
|
|
37,112 |
|
|
|
|
189,312 |
|
Present value discount
|
|
|
(26,007 |
) |
Lease liability
|
|
$ |
163,305 |
|
NOTE 6 - CONVERTIBLE NOTES PAYABLE
The carrying value of convertible notes payable, net of discount,
as of December 31, 2021 and June 30, 2021 was $721,055 and
$158,196, respectively, as summarized below:
The following table illustrates the carrying values for the
convertible notes payable as of December 31, 2021 and June 30,
2021:
|
|
December 31,
|
|
|
June 30,
|
|
Convertible Notes Payable
|
|
2021
|
|
|
2021
|
|
Convertible notes payable issued January 5, 2021 (6% interest)
|
|
$ |
- |
|
|
$ |
25,000 |
|
Convertible notes payable issued January 11, 2021 (6% interest)
|
|
|
- |
|
|
|
142,550 |
|
Convertible notes payable issued August 9, 2021 (6% interest)
|
|
|
- |
|
|
|
- |
|
Convertible notes payable issued August 10, 2021 (6% interest)
|
|
|
- |
|
|
|
- |
|
Convertible notes payable issued October 27, 2021 (0% interest) –
Auctus Fund LLC
|
|
|
6,050,000 |
|
|
|
- |
|
Total face value
|
|
|
6,050,000 |
|
|
|
167,550 |
|
Less unamortized discount
|
|
|
(5,328,945 |
) |
|
|
(9,354 |
) |
Carrying value
|
|
$ |
721,055 |
|
|
$ |
158,196 |
|
Between September 27, 2019 and August 10, 2021, the Company issued
convertible notes payable with an aggregate face value of $892,300,
of which $342,950 were issued by our subsidiary AAT. The notes have
a coupon rate of 6% and maturity dates between three and six
months. The agreements provided the holder has the option to
convert the principal balance and any accrued interest to common
stock of the Company. In the event the holder does not elect to
convert the note prior to maturity, the note will automatically
convert to common stock. Of the $892,300, $342,950 is convertible
at $.0033 per share, $87,000 is convertible at $0.025 per share,
$180,550 is convertible at $.03 per share, $31,800 is convertible
at $0.003 per share, and the remaining $250,000 is convertible at
$.06 per share
Between March 27, 2020 and July 11, 2021, holders of the
convertible notes converted the $342,950 in principal (the full
balance of the AAT Notes) and $10,290 in accrued interest into
107,042,708 shares of common stock. Between November 10, 2020 and
July 11, 2021, holders of the convertible notes converted $299,350
in principal and $7,224 in accrued interest into 19,641,327 shares
of common stock. During the six months ended December 31, 2021,
holders of the convertible notes converted $417,550 in principal
and $5,520 in accrued interest into 10,598,544 shares of common
stock. The remaining principal balance of the notes as of December
31, 2021 was $0. The Company have not issued the stock for the
conversion of $100,000 convertible notes payable issued on August
9, 2021 and $150,000 convertible notes payable issued on August 10,
2021 and recorded under common stock to be issued as of December
31, 2021.
The Company evaluated these notes under ASC 815 Derivatives and
Hedging (“ASC 815”). ASC 815 generally requires the analysis
embedded terms and features that have characteristics of
derivatives to be evaluated for bifurcation and separate accounting
in instances where their economic risks and characteristics are not
clearly and closely related to the risks of the host contract. None
of the embedded terms required bifurcation and liability
classification. However, the Company was required to determine if
the debt contained a beneficial conversion feature (“BCF”), which
is based on the intrinsic value on the date of issuance.
In
connection with the notes, the Company issued warrants to purchase
an aggregate 8,848,333 shares of common stock. The warrants have a
term of two years and an exercise price of $.025. The Company
evaluated the warrants under ASC 815 Derivatives and Hedging (“ASC
815”) and determined that they did not require liability
classification. The warrants were recorded in additional paid-in
capital under their aggregate relative fair value of $156,225.
The Company was required to determine if the debt contained a
beneficial conversion feature (“BCF”), which is based on the
intrinsic value on the date of issuance. After the allocation of
$156,225 to the warrants, the remaining $512,906 in proceeds
resulted in a beneficial conversion feature recorded in additional
paid-in capital. Both the BCF and warrants resulted in a debt
discount and are amortized over the life of the note.
For the six months ended December 31, 2021 and 2020, the Company
recorded $1,413,959 and $112,410 in amortization of debt discount
related to the notes. For the six months ended December 31, 2021
and 2020, the Company recorded $4,014 and $2,196 in interest
expense related to the notes, respectively.
Auctus Fund LLC
On
October 27, 2021, the Company issued a convertible note payable
with Auctus Fund, LLC (the “Auctus Note”) with the principal sum of
$6,050,000, which amount is the $5,142,500 actual amount of the
purchase price, hereof plus an original issue discount in the
amount of $907,500 and to pay interest on the unpaid principal
amount hereof at the rate of zero percent per annum from the issue
date until the note becomes due and payable, and $433,550 for
professional fees in completing the transactions, so the net
proceeds from the Auctus Fund LLC was $4,708,950. The note has a
maturity date of twelve months. The agreement provides the holder
has the option to convert the principal balance and any accrued
interest to common stock of the Company at a conversion price of
lesser of (i) $0.1187 or (ii) 75% of the offering price per share
divided by the number of shares of common stock.
In
connection with the notes, the Company issued warrants indexed to
an aggregate 50,968,828 shares of common stock. The
warrants have a term of five years and an exercise price of
$0.1187. The warrants were recorded at fair value of $2,777,081 to
additional-paid-in-capital in accordance with ASC 815-10 based upon
the allocation of the debt proceeds. The Company estimated the fair
value of the warrants using a Black-Scholes option-pricing model,
which is based, in part, upon subjective assumptions including but
not limited to stock price volatility, the expected life of the
warrants, the risk-free interest rate and the fair value of the
common stock underlying the warrants. The Company estimates the
volatility of its stock based on the average of three similar size
public companies peer group historical volatility that is in line
with the expected remaining life of the warrants. The risk-free
interest rate is based on the U.S. Treasury zero-coupon bond for a
maturity similar to the expected remaining life of the warrants.
The expected remaining life of the warrants is assumed to be
equivalent to their remaining contractual term.
The Company was required to determine if the debt contained a
beneficial conversion feature (“BCF”), which is based on the
intrinsic value on the date of issuance. The Company recorded
$2,365,419 conversion feature in additional paid-in capital. The
BCF resulted in a debt discount and are amortized over the life of
the note.
For the six months ended December 31, 2021, the Company recorded
$1,154,605 amortization of debt discount related to the Auctus
note.
NOTE 7 - RELATED PARTY TRANSACTIONS
Convertible notes
On
August 25, 2020, the Company issued a convertible note payable with
a face value of $5,000 with a coupon rate of 6% to Keystone
Business Development Partners, a Company owned by the Company’s
CFO, Brian Carey. The note has a maturity date of three months. The
agreement provides the holder has the option to convert the
principal balance and any accrued interest to common stock of the
Company at a conversion price of $.025 per share. In the event the
holder does not elect to convert the note prior to maturity, the
note will automatically convert to common stock at a price of $.025
per share.
The Company evaluated the agreement under ASC 815 Derivatives and
Hedging (“ASC 815”). ASC 815 generally requires the analysis
embedded terms and features that have characteristics of
derivatives to be evaluated for bifurcation and separate accounting
in instances where their economic risks and characteristics are not
clearly and closely related to the risks of the host contract. None
of the embedded terms required bifurcation and liability
classification.
In
connection with the note, the Company issued warrants indexed to an
aggregate 200,000 shares of common stock. The warrants have a term
of two years and an exercise price of $.025. The Company evaluated
the warrants under ASC 815 Derivatives and Hedging (“ASC 815”) and
determined that they did not require liability classification. The
warrants were recorded in additional paid-in capital under their
relative fair value of $2,461.
The Company was required to determine if the debt contained a
beneficial conversion feature (“BCF”), which is based on the
intrinsic value on the date of issuance. After the allocation of
$2,461 to the warrants, the remaining $2,539 in proceeds resulted
in a beneficial conversion feature recorded in additional paid-in
capital. Both the BCF and warrants resulted in a debt discount and
are amortized over the life of the note.
For the six months ended December 31, 2021 and 2020, the Company
recorded $0 and $5,000 in amortization of debt discount related to
the note. For the six months ended December 31, 2021 and 2020, the
Company recorded $0 and $76 in interest expense related to the
note, respectively.
On
November 25, 2020, Keystone Business Development Partners converted
$5,000 in principal and $76 in accrued interest into 203,024 shares
of common stock.
Consulting fees
During the three months ended December 31, 2021 and 2020, the
Company recorded $41,000 and $36,000 respectively, in consulting
fees to Ancient Investments, LLC, a Company owned by the Company’s
CEO, Keith Duffy and the Company’s Executive Director of Corporate
Operations, Scott Duffy.
For the three months ended December 31, 2021 and 2020, the Company
recorded $28,000 and $0 respectively, in consulting fees to Edward
DeFeudis, a Director of the Company.
During the three months ended December 31, 2021 and 2020, the
Company recorded $19,000 and $22,500 respectively, in consulting
fees to AMP Web Services, a Company owned by the Company’s CTO,
Pablo Lavigna.
During the three months ended December 31, 2021 and 2020, the
Company recorded $7,500 and $15,000 respectively, in consulting
fees to Keystone Business Development Partners, a Company owned by
the Company’s CFO, Brian Carey. As of December 31, 2021 and June
30, 2021, $30,000 and $25,000 was recorded in accrued liabilities
related to Keystone Business Development Partners,
respectively.
NOTE 8 - COMMITMENTS AND CONTINGENCIES
During the normal course of business, the Company may be exposed to
litigation. When the Company becomes aware of potential litigation,
it evaluates the merits of the case in accordance with FASB ASC
450-20-50, Contingencies. The Company evaluates its
exposure to the matter, possible legal or settlement strategies and
the likelihood of an unfavorable outcome. If the Company determines
that an unfavorable outcome is probable and can be reasonably
estimated, it establishes the necessary accruals.
Joint Venture
In
connection with the Eco-Aero, LLC Joint Venture, discussed in Note
3, the Company is obligated to invest $10,000,000 into the joint
venture.
Financial Advisory Agreements
On
August 10, 2021, the Company entered into an Advisory Agreement
with a firm to assist the Company with fundraising activities. In
connection with the agreement, the Company has the following
commitments:
|
·
|
to
issue 500,000 shares payable at the date of the agreement, 500,000
shares payable three months from the date of the agreement, 500,000
shares payable six months from the date of the agreement.
|
|
|
|
|
·
|
Pay a financing fee of 1.5% of gross proceeds received by the
Company up to $100,000,000; a financing fee of 1.25% of gross
proceeds received by the Company from $100,000,000-$200,000,000,
and a financing fee of 1% of gross proceeds received by the Company
over $200,000,000
|
|
|
|
|
·
|
M&A fee of 1.5% of the value of a business or asset sold up to
$50,000,000; an M&A fee of 1.25% of value of a business or
asset sold from $50,000,000-$100,000,000, an M&A fee of 1% of
value of a business or asset sold from $100,000,000-$200,000,000,
and an M&A fee of 0.5% of value of a business or asset sold
over $200,000,000
|
During the three and six months ended December 31, 2021, the
Company issued the initial 500,000 shares and second tranche of
500,000 shares.
On
August 19, 2021, the Company entered into an Advisory Agreement
with a firm to assist the Company with fundraising activities. In
connection with the agreement, the Company has the following
commitments:
|
·
|
Issue 2,225,000 common shares payable at the date of the agreement,
and 2,225,000 common shares payable upon an uplisting of the
Company’s common stock to a national exchange.
|
|
|
|
|
·
|
Pay a cash fee of seven percent 7% of the amount of capital raised,
invested or committed; and deliver a warrant (the “Agent Warrant”)
to purchase shares of the Common Stock equal to seven percent (7%)
of the number of shares of Common Stock underlying the securities
issued in the Financing.
|
|
|
|
|
·
|
Pay a cash fee for entering into a transaction including, without
limitation, a merger, acquisition or sale of stock or assets equal
to one and one half percent (1.5%), or in the event a transaction
is consummated with a party that was in communication with the
Company prior to the date of this contract, then the fee shall
equal one half percent (0.5%).
|
During the six months ended December 31, 2021, the Company issued
the initial 2,225,000 shares.
Litigation
On
September 1, 2021, Xeriant Inc. brought a cause of action in the
Southern District of Florida against a former shareholder for
claims, including but not limited to, breach of contract,
misrepresentation, and asserting claims to recoup monetary and
in-kind distributions made to the shareholder by the Company. The
defendant submitted an affirmative defense and counterclaim on
October 29, 2021.
Board of Advisor Agreements
The Company has entered into advisor agreements with various
advisory board members. The agreements provide for the
following:
On
October 27, 2020, the Company agreed to issue 300,000 common shares
immediately, 2-year cashless warrants to purchase 300,000 common
shares at the current price, and $2,500 per meeting paid 50% in
cash and 50% in common shares.
On
January 18, 2021, the Company agreed to issue 50,000 common shares,
two-year cashless warrants to purchase 25,000 common shares at the
current price, and $2,500 per meeting paid in cash, common shares,
or a combination.
On
January 22, 2021, the Company agreed to issue 50,000 common shares,
two-year cashless warrants to purchase 25,000 common shares at the
current price, and $2,500 per meeting paid in cash, common shares,
or a combination.
On
March 7, 2021 the Company paid an advisor $2,500 and issued 50,000
common shares.
On
July 1, 2021, the Company agreed to issue 100,000 common shares,
and $2,500 per meeting paid in cash, common shares, or a
combination, an additional bonus of $25,000 paid in common shares
issued at the end of each year of service, an option to purchase
5,000,000 common shares at $0.12 per share, vesting quarterly over
24 months, and for each of the following three years (beginning
July 1, 2022), an option to purchase an additional 1,000,000 common
shares per year thereafter at a 25% discount to the average market
price for the preceding 10 trading days.
On
July 6, 2021, provided an option to purchase 5,000,000 common
shares at $0.12 per share, vesting quarterly over 24 months, a
bonus of 250,000 common shares issued upon a strategic partnership
with a major airline, $2,500 per formal meeting paid in common
shares, and an additional bonus of $25,000 paid in common shares
issued at the end of each year of service.
On
July 28, 2021, the Company agreed to issue 250,000 common shares
immediately, an option to purchase 5,000,000 common shares at $0.12
per share, vesting quarterly over 24 months, a bonus of 5,000,000
common shares for bringing in a strategic partner that
significantly strengthens the Company’s market position, $2,500 per
formal meeting paid in cash, common shares or a combination, and an
additional bonus of $25,000 paid in common shares issued at the end
of each year of service
On
August 9, 2021, the Company agreed to issue 50,000 common shares,
$2,500 per meeting paid in cash, common shares, or a combination,
and an additional bonus of $25,000 paid in common shares issued at
the end of each year of service.
On
August 20, 2021, the Company agreed to issue 100,000 common shares,
and $2,500 per meeting paid in cash, common shares, or a
combination, an additional bonus of $25,000 paid in common shares
issued at the end of each year of service, an option to purchase
4,000,000 common shares at $0.12 per share, vesting quarterly over
24 months.
Other Previously Announced Joint Ventures and Letters of
Intent
The Company has announced its intention to enter into certain joint
ventures and partnerships over the past 12 months, namely Praga
Avia, CoFlow Jet, and TheIncLab. Due to the Company’s focus on its
joint development with XTI Aircraft Company, the advancement of
these partnerships has been put on hold. The Company anticipates
revisiting these opportunities after the completion of a public
offering when the Company is fully staffed and adequately financed.
The Company signed a term sheet in January 2022 with Movychem
s.r.o. for a joint venture. Both parties expect to sign a final
definite agreement in February 2022.
NOTE 9 - EQUITY
Common Stock
During the three months ended September 30, 2021, the Company
issued 400,000 shares of common stock related to a subscription
agreement from the previous fiscal year, which were previously
recorded in common stock to be issued at $48,000.
During the three months ended September 30, 2021, the Company sold
7,500,000 shares of common stock for aggregate proceeds of
$500,000, or $0.10per share.
In
connection with one of the subscription agreements, the Company
issued 250,000 shares as an equity kicker valued at $43,750, which
has been expensed as a financing costs.
During the three months ended September 30, 2021, the Company
issued 4,185,000 shares of common stock as a result of warrant
exercises in the aggregate proceeds of $125,550.
During the three months ended September 30, 2021, the Company
issued 4,000,000 shares of common stock in exchange for the
conversion of 4,000 shares of Series A Preferred Stock.
During the three months ended September 30, 2021, the Company
issued 10,598,544 shares of common stock for the conversion of
$167,550 in principal and $4,985 in accrued interest. This resulted
in a loss on extinguishment of debt in the amount of $535.
During the three months ended September 30, 2021, the Company
issued 2,825,000 shares of common stock for services, valued at
$449,200.
During the three months ended December 31, 2021, the Company sold
8,200,000 shares of common stock for aggregate proceeds of
$410,000, or $0.05 per share.
During the three months ended December 31, 2021, the Company issued
23,266,666 shares of common stock for aggregate proceeds of
$1,162,500, or $0.05 per share for the sale of common shares that
has not been issued in the quarter ended September 30, 2021.
During the three months ended December 31, 2021, the Company issued
123,600 shares of common stock for the $3,000 exercise of warrants
in the quarter ended September 30, 2021.
During the three months ended December 31, 2021, the Company issued
3,138,000 shares of common stock in exchange for the conversion of
3,318 shares of Series A Preferred Stock.
During the three months ended December 31, 2021, the Company issued
900,000 shares of common stock for services, valued at
$116,105.
Common Stock to be Issued
During the three months ended September 30, 2021, the Company
sold 200,000 shares of common stock for aggregate
proceeds of $6,000, or $0.03 per share. As of December 31,
2021, these shares are categorized in common stock to be
issued.
During the three months ended September 30, 2021, the Company
agreed to pay a consultant 250,000 shares in exchange to $45,500 in
services. As of December 31, 2021, these shares are categorized in
common stock to be issued.
During the three months ended September 30, 2021, the Company
agreed to issue advisory board members 250,000 shares in exchange
for $46,400 in services. 200,000 shares vest on a quarterly basis
over one year and 50,000 shares vest completely after a year. As of
December 31, 2021, these shares are categorized in common stock to
be issued.
During the three months ended December 31, 2021, the Company
received conversion of convertible notes payable of total
$250,000.
Series A Preferred Stock
There are 100,000,000 shares authorized as preferred stock, of
which 3,500,000 are designated as Series A Preferred Stock having a
par value of $0.00001 per share. The Series A preferred stock has
the following rights:
|
·
|
Voting: The
preferred shares shall be entitled to 100 votes to every one share
of common stock.
|
|
|
|
|
·
|
Dividends: The
Series A Preferred Stockholders are treated the same as the Common
Stock holders except at the dividend on each share of Series A
Convertible Preferred Stock is equal to the amount of the dividend
declared and paid on each share of Common Stock multiplied by the
Conversion Rate.
|
|
|
|
|
·
|
Conversion: Each
share of Series A Preferred Stock is convertible, at the option of
the holder thereof, at any time into shares of Common Stock on a
1:1,000 basis.
|
|
|
|
|
·
|
The shares of Series A Preferred Stock are redeemable at the option
of the Corporation at any time after September 30, 2022 upon not
less than 30 days written notice to the holders. It is not
mandatorily redeemable.
|
As
of December 31, 2021 and June 30, 2021, the Company has 781,132 and
788,270 shares of Series A Preferred Stock issued and outstanding,
respectively.
On
February 15, 2021, in accordance with Florida Law and conversations
with counsel, the Board of Directors of the Company rescinded
990,000 Series A Preferred Shares, which represented all preferred
shares issued to one of the shareholders in the Share Exchange
between American Aviation Technologies, LLC and Xeriant, Inc.
entered into on April 19, 2019, due to breach of contract.
During March of 2021, the remaining former members of American
Aviation Technologies, LLC agreed to allow the Company to rescind
an aggregate of 1,250,001 of their 1,760,000 Series A Preferred
Shares issued pursuant to the Share Exchange between American
Aviation Technologies, LLC and Xeriant, Inc., as a result of said
breach. As a result of the cancellation, the Company reduced the
investment in AAT by the value of these preferred shares.
During the six months ended December 31, 2021, the Company issued
3,138,000 shares of common stock in exchange for the conversion of
3,138 shares of Series A Preferred Stock.
Series B Preferred Stock
On
March 25, 2021, the Certificate of Designation for the Series B
Preferred was recorded by the State of Nevada. There are
100,000,000 shares authorized as preferred stock, of which
1,000,000 are designated as Series B Preferred Stock having a par
value of $0.00001 per share. The Series B preferred stock is not
convertible, does not have any voting rights and no liquidation
preference.
Stock Options
In
connection with certain advisory board compensation agreements, the
Company issued an aggregate 19,000,000 options at an exercise price
of $0.12 per share. These options vest quarterly over twenty-four
months and have a term of three years. The grant date fair value
was $3,543,787. The Company recorded compensation expense in the
amount of $1,887,545 for the six months ended December 31, 2021 for
these options.
As
of December 31, 2021, there are 19,000,000 options outstanding, of
which 2,375,000 are exercisable. The weighted averaged remaining
term is 2.55 years.
Significant inputs and results arising from the Black-Scholes
process are as follows for the options:
Quoted market price on valuation date
|
|
$0.169 - $0.23
|
|
Exercise prices
|
|
$ |
0.12 |
|
Range of expected term
|
|
1.55 Years – 2.49 Years
|
|
Range of market volatility:
|
|
|
|
|
Range of equivalent volatility
|
|
215.12%-275.73
|
%
|
Range of interest rates
|
|
0.20%-0.47
|
%
|
Warrants
As
of December 31, 2021 and June 30, 2021, the Company had 55,512,161
and 8,848,333 warrants outstanding, respectively. The warrants were
issued in connection with the Convertible Notes (See Note 6). The
warrants have a term of two to five years and an exercise price
range from $0.1187 to $.025. The Company evaluated the warrants
under ASC 815 Derivatives and Hedging (“ASC 815”) and determined
that they did not require liability classification. The warrants
were recorded in additional paid-in capital under their aggregate
relative fair value of $2,933,305. During the six months ended
December 31, 2021, holders of warrants exercised warrants for
4,305,000 shares of common stock for aggregate proceeds of
$128,550. As of December 31, 2021, the weighted average remaining
useful life of the warrants was 1.08.
NOTE 10 - NON-CONTROLLING INTEREST
AAT membership unit adjustment
On
May 12, 2021, on further advice of counsel and in good faith, the
Company returned 3,600,000 membership units of American Aviation
Technologies, LLC to a former shareholder, which was his
consideration provided in the Share Exchange between American
Aviation Technologies, LLC and Xeriant, Inc. As a result, this
former shareholder was restored to his original shareholding
position in American Aviation Technologies, LLC.
AAT Subsidiary
On
May 12, 2021, the Company’s position in American Aviation
Technologies, LLC was reduced to 64%, and therefore the subsidiary
is now classified as majority owned.
NOTE 11 - GOING CONCERN MATTERS
The Company’s financial statements are prepared using the generally
accepted accounting principles applicable to a going concern, which
contemplates the realization of assets and liquidation of
liabilities in the normal course of business. As of December
31, 2021 and June 30, 2021, the Company had $2,110,549 and $962,540
in cash and $1,305,399 and $677,257 in working capital,
respectively. For the six months ended December 31, 2021 and 2020,
the Company had a net loss of $9,974,398 and $1,520,421,
respectively. Continued losses may adversely affect the liquidity
of the Company in the future. Therefore, the factors noted above
raise substantial doubt about our ability to continue as a going
concern. The recoverability of a major portion of the recorded
asset amounts shown in the accompanying balance sheets is dependent
upon continued operations of the Company, which in turn is
dependent upon the Company’s ability to raise additional capital,
obtain financing and to succeed in its future operations. The
financial statements do not include any adjustments relating to the
recoverability and classification of recorded asset amounts or
amounts and classification of liabilities that might be necessary
should the Company be unable to continue as a going concern. The
Company’s existence is dependent upon management’s ability to
develop profitable operations and resolve its liquidity
problems.
NOTE 12 - SUBSEQUENT EVENTS
In
February 2022, the Company issued 4,229,680 common shares for
the conversion of convertible notes payable of total $250,000 and
additional 845,936 common shares as additional financing costs to
these two convertible holders.
In
February 2022, the Company issued 1,000,000 common shares from the
conversion of 1,000 Series A preferred stock.
Item
2. Management’s Discussion and Analysis of
Financial Condition and Results of
Operations
The following discussion of our financial condition and results
of operations should be read in conjunction with the audited and
unaudited financial statements and the notes to those statements
included elsewhere in this Report. This discussion contains
forward-looking statements that involve risks and uncertainties.
You should specifically consider the various risk factors
identified in this Report that could cause actual results to differ
materially from those anticipated in these forward-looking
statements.
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward looking
statements, including without limitation, statements related to our
plans, strategies, objectives, expectations, intentions and
adequacy of resources. Investors are cautioned that such
forward-looking statements involve risks and uncertainties
including without limitation the following: (i) our plans,
strategies, objectives, expectations and intentions are subject to
change at any time at our discretion; (ii) our plans and results of
operations will be affected by our ability to manage growth; and
(iii) other risks and uncertainties indicated from time to time in
our filings with the Securities and Exchange Commission.
In
some cases, you can identify forward-looking statements by
terminology such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘could,’’
‘‘expects,’’ ‘‘plans,’’ ‘‘intends,’’ ‘‘anticipates,’’ ‘‘believes,’’
‘‘estimates,’’ ‘‘predicts,’’ ‘‘potential,’’ or ‘‘continue’’ or the
negative of such terms or other comparable terminology. Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
levels of activity, performance, or achievements. Moreover, neither
we nor any other person assumes responsibility for the accuracy and
completeness of such statements. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof. We are under no duty to update any of
the forward-looking statements after the date of this Report.
This section of the report should be read together with Footnotes
of the Company audited financials for the year ended June 30, 2021.
The unaudited statements of operations for the three and six
months ended December 31, 2021 and 2020 are compared in the
sections below.
Brief Corporate History
Xeriant is an aerospace technology and advanced materials holding
and operating company focused on Advanced Air Mobility (“AAM”) and
the transition to green aerospace. The Company plans to source and
acquire complementary and strategic interests in visionary
companies developing, integrating, and commercializing critical
breakthrough technologies which enhance performance, increase
safety, and enable and support more efficient, autonomous, and
sustainable flight operations, including electrically powered
passenger and cargo transport aircraft capable of vertical takeoff
and landing. The Company is located at the Research Park at Florida
Atlantic University in Boca Raton, Florida.
The Company was originally incorporated in Nevada on December 18,
2009 under the name Eastern World Solutions, Inc. The name changed
to Banjo & Matilda, Inc. on September 24, 2013. Effective June
22, 2020 the Company changed its name from Banjo & Matilda,
Inc. to Xeriant, Inc.
On
April 16, 2019, the Company entered into a Share Exchange Agreement
with American Aviation Technologies, LLC (“AAT”), an aircraft
design and development company focused on the emerging segment of
the aviation industry of autonomous and semi-autonomous vertical
take-off and landing (VTOL) and unmanned aerial vehicles
(UAVs).
On
June 28, 2019, the Company spun out two wholly owned subsidiaries:
Banjo & Matilda (USA), Inc. and Banjo & Matilda Australia
Pty LTD.
On
September 30, 2019, the acquisition of AAT closed, and AAT became a
wholly owned subsidiary of the Company.
On
June 22, 2020, the name was changed from Banjo & Matilda, Inc.
to Xeriant, Inc.
On
May 27, 2021, the Company entered into a Joint Venture Agreement
with XTI Aircraft Company, to form a new company, called Eco-Aero,
LLC, for purpose of completing the preliminary design of XTI’s
TriFan 600, a 5-passenger plus pilot, hybrid electric, vertical
takeoff and landing (eVTOL) fixed wing aircraft.
On
May 31, 2021, the Company entered into a Joint Venture Agreement
with XTI Aircraft Company, to form a new company, called Eco-Aero,
LLC, for purpose of completing the preliminary design of XTI’s
TriFan 600, a 5-passenger plus pilot, hybrid electric, vertical
takeoff and landing (eVTOL) fixed wing aircraft.
Three months ended December 31, 2021 compared to the
three months ended December 31, 2020
|
|
For the three months ended
|
|
|
|
|
|
|
December 31,
2021
|
|
|
December 31,
2020
|
|
|
$
|
|
|
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing expense
|
|
$ |
46,623 |
|
|
$ |
1,027,109 |
|
|
$ |
(980,486 |
) |
|
|
95 |
% |
General and administrative expenses
|
|
|
1,120,250 |
|
|
|
37,469 |
|
|
|
1,082,781 |
|
|
|
2889.80 |
% |
Professional fees
|
|
|
102,484 |
|
|
|
14,637 |
|
|
|
87,848 |
|
|
|
600.18 |
% |
Related party consulting fees
|
|
|
130,925 |
|
|
|
41,500 |
|
|
|
89,425 |
|
|
|
215.48 |
% |
Research and development expense
|
|
|
2,859,644 |
|
|
|
- |
|
|
|
2,859,644 |
|
|
|
100 |
% |
Total operating expenses
|
|
|
4,259,926 |
|
|
|
1,120,715 |
|
|
|
3,139,211 |
|
|
|
280.11 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(4,259,926 |
) |
|
|
(1,120,715 |
) |
|
|
3,139,211 |
|
|
|
280.11 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of debt discount
|
|
|
(1,264,931 |
) |
|
|
(66,449 |
) |
|
|
(1,198,482 |
) |
|
|
1,803.61 |
% |
Amortization of debt discount, related party
|
|
|
- |
|
|
|
(3,044 |
) |
|
|
3,044 |
|
|
|
100 |
% |
Interest expense
|
|
|
(1,625 |
) |
|
|
(1,139 |
) |
|
|
(486 |
) |
|
|
42.67 |
% |
Interest expense, related parties
|
|
|
- |
|
|
|
(46 |
) |
|
|
(46 |
) |
|
|
100 |
% |
Gain on forgiveness of accounts payable
|
|
|
- |
|
|
|
(1,956 |
) |
|
|
1,956 |
|
|
|
100 |
% |
Loss on settlement of debt
|
|
|
(4 |
) |
|
|
- |
|
|
|
(4 |
) |
|
|
100 |
% |
Total other income (expense)
|
|
|
(1,266,560 |
) |
|
|
(72,634 |
) |
|
|
(1,193,926 |
) |
|
|
1,643.76 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(5,526,486 |
) |
|
|
(1,193,349 |
) |
|
|
(4,333,137 |
) |
|
|
363.11 |
% |
Sales and Marketing Expense
Sales and marketing expense was $46,623 for the three months ended
December 31, 2021 compared to $1,027,109 for the three months ended
December 31, 2020. During the three months ended December 31, 2021,
the Company was putting less money into investor relationship to
market the Company.
General and Administrative Expenses
Total general and administrative expenses were $1,120,250 for the
three months ended December 31, 2021 compared to $37,469 for the
three months ended December 31, 2020. The increase of $1,082,781
primarily relates to options valued at $827,221 for advisory board
services.
Professional Fees
Total professional fees were $102,484 for the three months ended
December 31, 2021 compared to $14,637 for the three months ended
December 31, 2020. The increase of $87,847 primary relates to legal
fees.
Related Party Consulting Fees
Total related party consulting fees were $130,925 for the three
months ended December 31, 2021 compared to $41,500 for the three
months ended December 31, 2020. The increase of $89,425 was
primarily related to $28,000 in new related party expenses coupled
with an increase in the pay of existing related party.
Research and Development Expenses
Total research and development expenses were $2,859,644 for the
three months ended December 31, 2021 compared to $0 for the three
months ended December 31, 2020. The research and development costs
were mainly related to the development of an aircraft through our
Eco-Aero joint venture and $92,746 expenditure to Movychem, a
Slovakian limited liability company for research and development in
advanced materials and chemicals.
Other Expenses
Total other income (expenses) were ($1,266,560) for the three
months ended December 31, 2021 compared to ($72,634) for the three
months ended December 31, 2020. Total other expenses consist of
interest expense on debt, amortization of debt and loss on
settlement of debt. The increase of $1,193,926 was primarily
related the Company recording amortization of debt discount during
the three months ended December 31, 2021 in the amount of
$1,264,931.
Net loss
Total net loss was $5,526,486 for the three months ended December
30, 2021 compared to $1,193,349 for the three months ended December
31, 2020. The increase of $4,333,137 was primarily due to research
and development expenses of $2,766,898 and equity based
compensation of $943,326.
Six months ended December 31, 2021 compared to the six
months ended December 31, 2020
|
|
For the six months ended
|
|
|
|
|
|
|
December 31,
2021
|
|
|
December 31,
2020
|
|
|
$
|
|
|
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing expense
|
|
$ |
645,218 |
|
|
$ |
1,027,109 |
|
|
$ |
(381,891 |
) |
|
|
37.18 |
% |
General and administrative expenses
|
|
|
2,321,252 |
|
|
|
73,439 |
|
|
|
2,247,813 |
|
|
|
3060.79 |
% |
Professional fees
|
|
|
132,025 |
|
|
|
35,237 |
|
|
|
96,788 |
|
|
|
274.68 |
% |
Related party consulting fees
|
|
|
213,425 |
|
|
|
78,000 |
|
|
|
135,425 |
|
|
|
173.62 |
% |
Research and development expense
|
|
|
5,200,219 |
|
|
|
- |
|
|
|
5,200,219 |
|
|
|
100 |
% |
Total operating expenses
|
|
|
8,512,139 |
|
|
|
1,213,785 |
|
|
|
7,298,354 |
|
|
|
601.29 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(8,512,139 |
) |
|
|
(1,213,785 |
) |
|
|
7,298,354 |
|
|
|
601.29 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of debt discount
|
|
|
(1,413,959 |
) |
|
|
(112,410 |
) |
|
|
(1,301,549 |
) |
|
|
1,157.86 |
% |
Amortization of debt discount, related party
|
|
|
- |
|
|
|
(5,000 |
) |
|
|
5,000 |
|
|
|
100 |
% |
Financing fees
|
|
|
(43,750 |
) |
|
|
- |
|
|
|
(43,750 |
) |
|
|
100 |
% |
Interest expense
|
|
|
(4,014 |
) |
|
|
(2,196 |
) |
|
|
(1,818 |
) |
|
|
82.79 |
% |
Interest expense, related parties
|
|
|
- |
|
|
|
(76 |
) |
|
|
76 |
|
|
|
100 |
% |
Loss on settlement of debt
|
|
|
(536 |
) |
|
|
(186,954 |
) |
|
|
186,418 |
|
|
|
99.71 |
% |
Total other income (expense)
|
|
|
(1,462,259 |
) |
|
|
(306,636 |
) |
|
|
(1,155,623 |
) |
|
|
376.87 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(9,974,398 |
) |
|
|
(1,520,421 |
) |
|
|
(8,453,977 |
) |
|
|
556.03 |
% |
Sales and Marketing Expense
Sales and marketing expense was $645,218 for the six months ended
December 31, 2021 compared to $1,027,109 for the six months ended
December 31, 2020. During the six months ended December 31, 2021,
the Company was putting money into sales and marketing expenses to
actively market the brand.
General and Administrative Expenses
Total general and administrative expenses were $2,321,252 for the
six months ended December 31, 2021 compared to $73,439 for the six
months ended December 31, 2020. The increase of $2,247,813
primarily relates to options valued at $1,887,545 for advisory
board services and $657,204 from stock issued for services.
Professional Fees
Total professional fees were $132,025 for the six months ended
December 31, 2021 compared to $35,237 for the six months ended
December 31, 2020. The increase of $96,789 primary relates to legal
fees.
Related Party Consulting Fees
Total related party consulting fees were $213,425 for the six
months ended December 31, 2021 compared to $78,000 for the six
months ended December 31, 2020. The increase of $135,425 was
primarily related to $28,000 in new related party expenses coupled
an increase in the pay of existing related party.
Research and Development Expenses
Total research and development expenses were $5,200,219 for the six
months ended December 31, 2021 compared to $0 for the six months
ended December 31, 2020. The research and development costs were
related to the development of an aircraft through our Eco-Aero
joint venture and $142,790 expenditure to Movychem, a Slovakian
limited liability company for research and development in advanced
materials and chemicals.
Other Expenses
Total other income (expenses) were ($1,462,259) for the six months
ended December 31, 2021 compared to ($306,636) for the six months
ended December 31, 2020. Total other expenses consist of interest
expense on debt, amortization of debt and loss on settlement of
debt. The increase of $1,155,623 was primarily related the Company
recording amortization of debt discount during the six months ended
December 31, 2021 in the amount of $1,413,959.
Net loss
Total net loss was $9,974,398 for the six months ended December 30,
2021 compared to $1,520,421 for the six months ended December 31,
2020. The increase of $8,453,977 was primarily due to research and
development expenses of $5,200,219 and equity based compensation of
$2,544,750.
Liquidity and Capital Resources
Operating Activities
Cash used in operations of $6,013,001 during the six months ended
December 31, 2021 was primarily resulted from the increase cash
used in operations resulted from increased expenditures on research
and development expense. The Company has a net loss of $9,974,398
during the six months ended December 31, 2021 and offset by
non-cash expenses such as stock compensation expense of $1,887,545,
stock issued for services of $657,204, and amortization of debt
discounts of $1,413,959.
Cash used in operations of $162,557 during the six months ended
December 31, 2020 was primarily a result of our $1,520,421 net loss
reconciled with our net non-cash expenses relating to amortization
of debt discount and our changes in operating assets and
liabilities relating to accounts payable and accrued
liabilities.
Investing Activities
Net cash used in investing activities for the six months ended
December 31, 2021 was $4,990, which consisted of purchase of new
equipment.
Financing Activities
Net cash provided by financing activities for the six months ended
December 31, 2021 was $7,166,000, which consisted of proceeds from
the sale of common stock of $2,078,500, cash in the amount of
$128,550 from the exercise of warrants, and issuance of convertible
debt of $4,958,950.
Net cash provided by financing activities for the six months ended
December 31, 2020 was $143,300, which consisted of proceeds from
the sale of common stock of $51,000 and issuance of convertible
debt of $92,300.
The Company’s financial statements are prepared using the generally
accepted accounting principles applicable to a going concern, which
contemplates the realization of assets and liquidation of
liabilities in the normal course of business. At December 31, 2021
and June 30, 2021, the Company had $2,110,549 and $962,540 in cash
and $1,305,399 and $677,257 in working capital, respectively. For
the six months ended December 31, 2021 and 2020, the Company had a
net loss of $9,974,398 and $1,520,421, respectively. Continued
losses may adversely affect the liquidity of the Company in the
future. Therefore, the factors noted above raise substantial doubt
about our ability to continue as a going concern. The
recoverability of a major portion of the recorded asset amounts
shown in the accompanying balance sheets is dependent upon
continued operations of the Company, which in turn is dependent
upon the Company’s ability to raise additional capital, obtain
financing and to succeed in its future operations. The financial
statements do not include any adjustments relating to the
recoverability and classification of recorded asset amounts or
amounts and classification of liabilities that might be necessary
should the Company be unable to continue as a going concern. The
Company’s existence is dependent upon management’s ability to
develop profitable operations and resolve its liquidity
problems.
Commitments for Capital Expenditures
To
date, our operations have been funded primarily through private
investors. We have had a number of discussions with investment
banker and institutional investment, which is to acquire and
develop breakthrough technologies or business interests in those
companies that have developed these technologies. There is no
assurance that the Company will be able to obtain such funding
and/or working capital. To the extent that funding is not
available, the Company will be required to scale back or
discontinue its business plan. Even if the Company is able to
obtain financing, it may contain undue restrictions of the
Company’s operations, or there may be substantial dilution for our
shareholders in the case of equity financing or convertible debt
financing.
Off Balance Sheet Items
We
do not have any off-balance sheet arrangements, financings, or
other relationships with unconsolidated entities or other persons,
also known as “special purpose entities” (SPEs).
Quantitative and Qualitative Disclosures about Market
Risk
In
the ordinary course of our business, we are not exposed to market
risk of the sort that may arise from changes in interest rates or
foreign currency exchange rates, or that may otherwise arise from
transactions in derivatives.
The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and
expenses during the reporting period. The most significant
assumptions and estimates relate to the valuation of beneficial
conversion features and warrants associated with convertible debt.
Actual results could differ from these estimates.
Contingencies
Certain conditions may exist as of the date the financial
statements are issued, which may result in a loss to the Company,
but which will only be resolved when one or more future events
occur or fail to occur. Our management, in consultation with its
legal counsel as appropriate, assesses such contingent liabilities,
and such assessment inherently involves an exercise of judgment. In
assessing loss contingencies related to legal proceedings that are
pending against us or unasserted claims that may result in such
proceedings, we, in consultation with legal counsel, evaluates the
perceived merits of any legal proceedings or unasserted claims, as
well as the perceived merits of the amount of relief sought or
expected to be sought therein. If the assessment of a contingency
indicates it is probable that a material loss has been incurred and
the amount of the liability can be estimated, then the estimated
liability would be accrued in our financial statements. If the
assessment indicates a potentially material loss contingency is not
probable, but is reasonably possible, or is probable, but cannot be
estimated, then the nature of the contingent liability, together
with an estimate of the range of possible loss, if determinable and
material, would be disclosed. Loss contingencies considered remote
are generally not disclosed unless they involve guarantees, in
which case the guarantees would be disclosed.
On
September 1, 2021, Xeriant Inc. brought a cause of action in the
Southern District of Florida against a former shareholder for
claims, including but not limited to, breach of contract,
misrepresentation, and asserting claims to recoup monetary and
in-kind distributions made to the shareholder by the Company. The
defendant in the above-mentioned action has not asserted any
counterclaims to-date.
Item 3. Quantitative and Qualitative
Disclosures About Market Risk.
As
a smaller reporting company, the Company has elected not to provide
the disclosure required by this item.
Item 4. Controls and
Procedures.
Disclosure Controls and Procedures
Our management is responsible for maintaining disclosure controls
and procedures that are designed to ensure that information
required to be disclosed in the reports that the Registrant files
or submits under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in the
SEC’s rules and forms. In addition, the disclosure controls and
procedures must ensure that such information is accumulated and
communicated to the Registrant’s management, including its Chief
Executive Officer and Chief Financial Officer, as appropriate, to
allow timely decisions regarding required financial and other
required disclosures.
At
December 31, 2021, an evaluation of the effectiveness of our
disclosure controls and procedures (as defined in Rules 13(a)-15(e)
and 15(d)-15(e) of the Exchange Act) was carried out under the
supervision and with the participation of Keith Duffy our Chief
Executive Officer and Brian Carey our Chief Financial Officer.
Based on his evaluation of our disclosure controls and procedures,
he concluded that at December 31, 2021, our disclosure controls and
procedures are not effective due to material weaknesses in our
internal controls over financial reporting discussed directly
below.
Changes in Internal Control Over Financial
Reporting
There has been no change in the Company’s internal control over
financial reporting, as defined in Rules 13a-15(f) of the Exchange
Act, during the Company’s most recent fiscal quarter ended December
31, 2021, that has materially affected, or is reasonably likely to
materially affect, the Company’s internal control over financial
reporting.
PART II – OTHER INFORMATION
Item 1. Legal
Proceedings
None.
Item 1A. Risk Factors
Our business is subject to numerous risks and uncertainties
including but not limited to those discussed in “Risk Factors” in
our Annual Report on Form 10-K.
Item 2. Unregistered Sales of Equity
Securities
During the three months ended September 30, 2021, the Company
issued 400,000 shares of common stock related to a subscription
agreement from the previous fiscal year, which were previously
recorded in common stock to be issued at $48,000.
During the three months ended September 30, 2021, the Company sold
2,500,000 shares of common stock for aggregate proceeds of
$250,000, or $0.10 per share.
During the three months ended September 30, 2021, the Company sold
5,000,000 shares of common stock for aggregate proceeds of
$250,000, or $0.05 per share.
In
connection with one of the subscription agreements, the Company
issued 250,000 shares as an equity kicker valued at $43,750, which
has been expensed as a financing costs.
During the three months ended September 30, 2021, the Company
issued 4,185,000 shares of common stock as a result of warrant
exercises in the aggregate proceeds of $125,550.
During the three months ended September 30, 2021, the Company
issued 4,000,000 shares of common stock in exchange for the
conversion of 4,000 shares of Series A Preferred Stock.
During the three months ended September 30, 2021, the Company
issued 10,598,544 shares of common stock for the conversion of
$167,550 in principal and $4,985 in accrued interest. This resulted
in a loss on extinguishment of debt in the amount of $535.
During the three months ended September 30, 2021, the Company
issued 2,825,000 shares of common stock for services, valued at
$449,200.
During the three months ended December 31, 2021, the Company sold
8,200,000 shares of common stock for aggregate proceeds of
$410,000, or $0.05 per share.
During the three months ended December 31, 2021, the Company issued
23,266,667 shares of common stock for aggregate proceeds of
$1,162,500, or $0.05 per share for the sale of common shares that
has not been issued in the quarter ended September 30, 2021.
During the three months ended December 31, 2021, the Company issued
4,305,000 shares of common stock for the $3,000 exercise of
warrants in the quarter ended September 30, 2021.
During the three months ended December 31, 2021, the Company issued
3,138,000 shares of common stock in exchange for the conversion of
3,318 shares of Series A Preferred Stock.
During the three months ended December 31, 2021, the Company issued
900,000 shares of common stock for services, valued at
$116,105.
Item 3. Defaults Upon Senior
Securities
None.
Item 4. Mine Safety
Disclosures
None.
Item 5. Other
Information
None.
Item 6. Exhibits
The following exhibits are filed herewith
*
|
Incorporated by reference to the Company’s Current Report on Form
8-K filed on November 4, 2021
|
SIGNATURES
In
accordance with the requirements of the Exchange Act, the Company
caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
XERIANT, INC.
|
|
|
|
|
Date: February 14, 2022
|
By:
|
/s/ Keith Duffy
|
|
|
|
Keith Duffy
Chief Executive Officer
(Principal Executive)
|
|
Date: February 14, 2022
|
By:
|
/s/ Brian Carey
|
|
|
|
Brian Carey
Chief Financial Officer
|
|
Xeriant (QB) (USOTC:XERI)
Historical Stock Chart
From Jan 2023 to Feb 2023
Xeriant (QB) (USOTC:XERI)
Historical Stock Chart
From Feb 2022 to Feb 2023